
Adagene ADAG
€ 2.37
-2.75%
Geschäftsbericht 2024
hinzugefügt 17.01.2026
Adagene Abschreibung & Amortisation 2011-2026 | ADAG
Abschreibung & Amortisation Jährlich Adagene
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 723 K | 980 K | 1.15 M | 1.13 M | 858 K | 817 K | 909 K | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.15 M | 723 K | 937 K |
Abschreibung & Amortisation anderer Aktien in der Pharmaeinzelhändler
| Name | Abschreibung & Amortisation | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | ||
|
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M | ||
|
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | ||
|
Biogen
BIIB
|
673 M | $ 177.27 | 0.62 % | $ 25.8 B | ||
|
ANI Pharmaceuticals
ANIP
|
67.7 M | $ 81.19 | -0.98 % | $ 1.57 B | ||
|
Amgen
AMGN
|
5.59 B | $ 339.82 | -0.91 % | $ 182 B | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Aytu BioScience
AYTU
|
5.38 M | $ 2.56 | -0.78 % | $ 16.1 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
CASI Pharmaceuticals
CASI
|
468 K | $ 0.99 | - | $ 135 M | ||
|
Catalyst Biosciences
CBIO
|
1.07 M | $ 10.0 | -1.43 % | $ 658 M | ||
|
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | ||
|
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | ||
|
Cerus Corporation
CERS
|
1.86 M | $ 2.3 | -1.08 % | $ 424 M | ||
|
Aptose Biosciences
APTO
|
32 K | - | -45.71 % | $ 1.2 M | ||
|
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | ||
|
Brickell Biotech
BBI
|
41 K | - | -5.38 % | $ 6.06 M | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
Beam Therapeutics
BEAM
|
21.9 M | $ 28.26 | -3.52 % | $ 2.33 B | ||
|
Athira Pharma
ATHA
|
970 K | - | - | $ 269 M | ||
|
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
22.2 M | $ 68.89 | -0.33 % | $ 9.21 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
397 K | $ 24.53 | -0.2 % | $ 2.91 B | ||
|
Cardiff Oncology
CRDF
|
404 K | $ 1.68 | 3.75 % | $ 80.1 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
131 K | - | -10.17 % | $ 12.2 K | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
11 K | - | -9.72 % | $ 5.89 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
9.45 M | - | -15.15 % | $ 60.3 M | ||
|
Berkeley Lights
BLI
|
9 M | - | -7.31 % | $ 87 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 K | $ 4.03 | -1.71 % | $ 8.77 B | ||
|
Amneal Pharmaceuticals
AMRX
|
62.6 M | $ 13.77 | -2.45 % | $ 4.25 B | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B |